Montai Health

Montai Health leverages AI-driven platforms to discover and optimize small molecule therapeutics derived from naturally occurring compounds with established safety profiles. Their approach focuses on chronic disease areas where current therapies are insufficient or inaccessible. The company’s CONECTA™ platform enables rapid identification and optimization of drug leads by mapping bioactive molecules already present in foods and supplements to validated disease pathways. Initial focus areas include inflammatory and autoimmune conditions; additional work spans oncology, neurology, and metabolism. As of now, no clinical results have been published; pipeline programs are preclinical.